Division of Immunology, Transplantation and Infectious Diseases, IRCCS Ospedale San Raffaele Scientific Institute, Milan, Italy.
Unit of Nephrology, IRCCS Ospedale San Raffaele, Milan, Italy.
Aging (Albany NY). 2020 Nov 26;12(23):23497-23508. doi: 10.18632/aging.202200.
Sarcopenia is a hallmark of aging. Inflammation due to increased generation of cytokines such as TNFα, IL-1β and IL-6 has been implicated in the pathogenesis of sarcopenia. In skeletal muscle of C57BL/6 mice from 12 until 28 months of age, we observed a progressive reduction of myofiber cross sectional area, loss of type II fibers and infiltration by inflammatory cells. Muscle strength decreased in parallel. Pharmacological TNFα blockade by weekly subcutaneous injection of Etanercept from 16 to 28 months of age prevented atrophy and loss of type II fibers, with significant improvements in muscle function and mice lifespan. The effects on leukocyte recruitment were limited. These results provide a proof of principle that endogenous TNFα is sufficient to cause sarcopenia and to reduce animal survival, and open a novel perspective on novel potential pharmacological treatment strategies based on TNFα blockade to prevent the noxious events associated with aging.
肌肉减少症是衰老的标志。由于 TNFα、IL-1β 和 IL-6 等细胞因子的产生增加而导致的炎症,与肌肉减少症的发病机制有关。在 12 至 28 个月大的 C57BL/6 小鼠的骨骼肌中,我们观察到肌纤维横截面积逐渐减少,II 型纤维丧失以及炎症细胞浸润。肌肉力量也随之下降。从 16 个月到 28 个月,每周通过皮下注射依那西普进行 TNFα 药理学阻断,可防止萎缩和 II 型纤维丧失,并显著改善肌肉功能和小鼠寿命。对白细胞募集的影响是有限的。这些结果提供了一个原理上的证明,即内源性 TNFα足以导致肌肉减少症并降低动物的存活率,并为基于 TNFα 阻断的新型潜在药物治疗策略开辟了新的视角,以预防与衰老相关的有害事件。